NeuBase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity

Consolidated Statements of Stockholders' Equity (USD $)	Setries B Preferred Stock	Common Stock [Member]	Additional Paid-in Capital	Stock Subscription Receivable	Accumulated Deficit	Total
Balance, beginning at Sep. 30, 2011	$ 558	$ 1,324	$ 22,291,877		$ (27,075,512)	$ (4,781,753)us-gaap_StockholdersEquity
Balance, beginning, shares at Sep. 30, 2011	5,583,336	13,234,194
Common stock and warrants issued for cash		61	958,469			958,530
Common stock and warrants issued for cash, shares		611,114
Fair value of employee stock options			406,267			406,267
Common stock issued in conversion of warrants		177	2,914,274	(11,891)		2,902,560
Common stock issued in conversion of warrants, shares		1,774,999
Common stock and warrants issued in advance of services		13	941,398			941,411
Common stock and warrants issued in advance of services, shares		132,589
Adjustment for derivative liability			3,454,094			3,454,094
Net income (loss) for the year					(1,454,884)	(1,454,884)us-gaap_NetIncomeLoss
Balance, ending at Sep. 30, 2012	558	1,575	30,966,379	(11,891)	(28,530,396)	2,426,225us-gaap_StockholdersEquity
Balance, ending, shares at Sep. 30, 2012	5,583,336	15,752,896
Fair value of employee stock options			746,262			746,262
Common stock issued in exercise of warrants		214	5,239,650			5,239,864
Common stock issued in exercise of warrants, shares		2,131,784
Termination of derivative liability			1,886,338			1,886,338
Common stock issued for services		5	270,162			270,167
Common stock issued for services, shares		52,433
Adjustment for derivative liability			335,869			335,869
Conversion of preferred series B to common stock	(508)	169	339
Conversion of preferred series B to common stock, shares	(5,083,336)	1,694,446
Exercise of director options		11	(11)
Exercise of director options, shares		109,982
Proceeds received for subscription receivable				11,891		11,891
Net income (loss) for the year					(5,652,488)	(5,652,488)us-gaap_NetIncomeLoss
Balance, ending at Sep. 30, 2013	50	1,974	39,444,988		(34,182,884)	5,264,128us-gaap_StockholdersEquity
Balance, ending, shares at Sep. 30, 2013	500,000	19,741,541
Fair value of employee stock options			2,074,487			2,074,487
Common stock issued in exercise of warrants		11	260,741			260,752
Common stock issued in exercise of warrants, shares		106,056
Cashless exercise of warrants		223	(223)
Cashless exercise of warrants, shares		2,238,782
Common stock issued for settlement of accounts payable		1	49,999			50,000
Common stock issued for settlement of accounts payable, shares		6,282
Common stock issued for cash		180	16,875,820			16,876,000
Common stock issued for cash, shares		1,800,000
Common stock issued for acquisition of assets		119	10,180,105			10,180,224
Common stock issued for acquisition of assets, shares		1,194,862
Warrants issued for service			1,177,095			1,177,095
Conversion of preferred series B to common stock	(50)	17	33
Conversion of preferred series B to common stock, shares	(500,000)	166,667
Net income (loss) for the year					(9,130,664)	(9,130,664)us-gaap_NetIncomeLoss
Balance, ending at Sep. 30, 2014		$ 2,525	$ 70,063,045		$ (43,313,548)	$ 26,752,022us-gaap_StockholdersEquity
Balance, ending, shares at Sep. 30, 2014		25,254,190